JAK3 and ataxia telangiectasia: The control group consisted of 25 patients with AT, 37 patients with NBS, 1 patient with XLA and 2 patients with SCID, i.e. one with JAK3 deficiency (T-B+) and one with DCLRE1C (Artemis) deficiency (T-Blow).